Arca
Skip to content
Tools
Tools

Hearing loss

Drug research and approvals for hearing loss: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 212 studies of hearing loss are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 9 open orphan designations naming it.

  • Recruiting worldwide: 212
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 212 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 1

Phase 2 10

Phase 1 or earlier 7

How its trials ended

1,070 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 178 whose ending is known, 42% met their primary endpoint, 3% missed it and 55% stopped early.

  • Completed, result not reported46944%
  • Ongoing27526%
  • Status unknown14814%
  • Met its primary endpoint747%
  • Stopped: other or unclear707%
  • Stopped: enrollment or feasibility141%
  • Missed its primary endpoint61%
  • Stopped: lack of efficacy61%
  • Stopped: sponsor or business decision4<1%
  • Stopped: funding3<1%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 25, 2026A trial of AAVANC80-hotof gene therapy in individuals with sensorineural hearing loss due to otoferlin gene (OTOF) mutationsAAVANC80-HOTOFEli LillyPending
May 1, 2026Usability of the intracochlear catheter incat a pilot feasability studyDexamethasone / N-acetylcysteine / TriamcinoloneSunnybrook Research InstitutePending
Nov 29, 2024Usability of the intracochlear catheter incat - a pilot feasibility studyDexamethasone / Triamcinolone / AcetylcysteineSunnybrook Research InstitutePending
Nov 15, 2024A phase I/II clinical trial with SENS-501 in children suffering from severe to profound hearing loss due to otoferlin (OTOF) mutationsSENS-501SensorionPending
Sep 28, 2018A two-part, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of SENS-401 in subjects with severe or profound sudden…Azasetron (SENS-401)SensorionClosed

FDA orphan designations

Approved first, then open designations, newest first
Apr 23, 2026OtarmeniTreatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL)…Regeneron Pharmaceuticals, Inc.Approved
Jul 9, 2026Adeno-associated viral vector containing the hOTOF gene…Treatment of otoferlin (OTOF)-related hearing lossEmaygeneDesignated
Aug 6, 2024Dual vector gene therapy product containing recombinant…Treatment of otoferlin-mediated hearing LossSuzhou Otovia Therapeutics Co., Ltd.Designated
Feb 29, 2024A novel CRISPR/Cas13X RNA base-editing therapy drugTreatment of OTOF Q829X mutation-induced hearing lossCholgene Therapeutics, Inc.Designated
Dec 21, 2023Dual recombinant adeno-associated viral vectors encoding…Treatment of otoferlin-mediated hearing lossShanghai Refreshgene Therapeutics Co., Ltd.Designated
Nov 29, 2022A dual vector gene therapy product containing AAV8 vectors…Treatment of otoferlin related hearing lossSensorion S.A.Designated
May 10, 20216-fluoro-9-methyl-9H-pyrido[3,4-b]-indoleTreatment of Sudden Sensorineural Hearing LossAudioCure Pharma GmbHDesignated
Apr 12, 2021Melurotogene parvecTreatment of patients with otoferlin gene (OTOF)-mediated hearing lossEli Lilly and CompanyDesignated
Dec 12, 2019PioglitazoneTreatment of sudden sensorineural hearing lossStrekin AGDesignated
Mar 28, 2006(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor)Treatment of acute sensorineural hearing lossAltamira Therapeutics Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.